News
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Heidelberg Pharma receives USD 25 million upfront cash payment from HealthCare Royalty for royalty purchase agreement. Funds to advance ADC pipeline development and extend cash runway -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Heidelberg Pharma progresses into Cohort 6 with ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study, showing first objective responses and partial remissions. Amended protocol includes optimized dosing regimens -
-
